Skip to main content
OpenTrials
Completed

NCT Number: NCT00239473

12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD

The primary objective was to compare the bronchodilator efficacy of two doses (5 mcg and 10 mcg) of tiotropium inhalation solution delivered by the Respimat inhaler once daily to placebo and to ipratropium bromide MDI four times daily in patients with COPD. The secondary objective was to compare the safety of tiotropium inhalation solution delivered by the Respimat to placebo and ipratropium bromide MDI.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pulmonary Disease, Chronic Obstructive Chronic Disease Disease Attributes Lung Diseases Lung Diseases, Obstructive Pathologic Processes Pathological Conditions, Signs and Symptoms Respiratory Tract Diseases

Age range

40 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Boehringer Ingelheim Investigational Site, Berlin, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Outpatients of either sex, aged >/= 40 years with a diagnosis of COPD (FEV1 </= 60% predicted [ECCS criteria] and FEV1/FVC </= 70%)

Treatment and study plan

5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler

Device

10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler

Device

Primary outcomes

  1. Trough FEV1 response

    Time frame: after 12 weeks

Secondary outcomes

  1. Trough FEV1 response

    Time frame: after 1, 4 and 8 weeks

  2. Trough FVC response

    Time frame: after 1, 4, 8 and 12 weeks

  3. FEV1 and FVC area under the curve (AUC)0-6h and peak response

    Time frame: after 0, 1, 4, 8 and 12 weeks

  4. Individual FEV1 and FVC measurements

    Time frame: during 12 weeks

  5. Onset and duration of therapeutic response and percentage of responders

    Time frame: after 0 and 12 weeks

  6. Weekly mean pre-dose morning and evening PEFR (peak expiratory flow rate)

    Time frame: up to 12 weeks

  7. Weekly mean number of occasions of rescue therapy used per day (PRN salbutamol)

    Time frame: up to 12 weeks

  8. COPD symptom scores (wheezing, shortness of breath, coughing and tightness of chest)

    Time frame: up to 15 weeks

  9. Physician's Global Evaluation

    Time frame: up to 15 weeks

  10. Number of patients with at least one exacerbation of COPD

    Time frame: up to 15 weeks

  11. Time to first exacerbation

    Time frame: up to 15 weeks

  12. Number of exacerbations and exacerbation days

    Time frame: up to 15 weeks

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Official study title

A Randomised, Double-Blind, Double-Dummy, Placebo- and Active-Controlled, Parallel Group Efficacy and Safety Comparison of 12-Week Treatment of Two Doses [5 μg (2 Actuations of 2.5 μg) and 10 μg (2 Actuations of 5 μg)] of Tiotropium Inhalation Solution Delivered by the Respimat Inhaler, Placebo and Ipratropium Bromide Inhalation Aerosol (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Important dates

Study start
2002
Primary completion
2003
First posted
Oct 17, 2005
Registry last updated
Nov 1, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.